Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
GNLX

GNLX - GENELUX CORPORATION Stock Price, Fair Value and News

$2.76-0.20 (-6.76%)
Market Closed

17/100

GNLX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

17/100

GNLX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.3

Target 3M

$2.58

Target 6M

$2.44

GNLX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GNLX Price Action

Last 7 days

-2.5%

Last 30 days

-37.0%

Last 90 days

-65.3%

Trailing 12 Months

-29.6%

GNLX RSI Chart

GNLX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GNLX Valuation

Market Cap

105.0M

Price/Earnings (Trailing)

-3.29

Price/Sales (Trailing)

394.09

Price/Free Cashflow

-4.35

GNLX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.3

Target 3M

$2.58

Target 6M

$2.44

GNLX Fundamentals

GNLX Revenue

Revenue (TTM)

757.0K

GNLX Earnings

Earnings (TTM)

-31.9M

Earnings Growth (Yr)

-22.93%

Earnings Growth (Qtr)

-6.63%

GNLX Profitability

Return on Equity

-171.45%

Return on Assets

-127.56%

Free Cashflow Yield

-23%

GNLX Investor Care

Shares Dilution (1Y)

10.17%

Diluted EPS (TTM)

-0.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024235.8K409.5K583.3K757.0K
20238.3M5.6M2.8M62.0K
202200011.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About GENELUX CORPORATION

GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
 CEO
 WEBSITEgenelux.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES20

GENELUX CORPORATION Frequently Asked Questions

GNLX is the stock ticker symbol of GENELUX CORPORATION. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of GENELUX CORPORATION is 105.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check GNLX's fair value in chart for subscribers.

The fair value guage provides a quick view whether GNLX is over valued or under valued. Whether GENELUX CORPORATION is cheap or expensive depends on the assumptions which impact GENELUX CORPORATION's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GNLX.

As of Wed Jan 28 2026, GNLX's PE ratio (Price to Earnings) is -3.29 and Price to Sales (PS) ratio is 394.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GNLX PE ratio will change depending on the future growth rate expectations of investors.